<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
SEPTEMBER 5, 2000
-----------------------------------------------------------------
Date of Report (Date of earliest event reported)
INHALE THERAPEUTIC SYSTEMS, INC.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 023556 94-3134940
------------------------------- ------------ -------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
150 Industrial Road
SAN CARLOS, CA 94070
----------------------------------------
(Address of principal executive offices)
(650) 631-3100
----------------------------------------------------
(Registrant's telephone number, including area code)
----------------------------------------------------
(Former name, if changed since last report)
1.
<PAGE>
ITEM 5. OTHER EVENTS
On September 5, 2000, Inhale Therapeutic Systems, Inc. ("Inhale")
announced its re-initiation with Eli Lilly and Company ("Lilly") of the
development and License Agreement of an inhaled formulation of
Forteo-TM-recombinant parathyroid hormone (PTH). Inhale also announced that
Lilly has decided to discontinue work on an unspecified inhaleable protein
product that was in pre-clinical development with Inhale. A press release
relating to these matters is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated September 5, 2000
2.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INHALE THERAPEUTIC SYSTEMS, INC.
Dated: September 5, 2000 By: /s/ AJIT S. GILL
----------------------------------------
Ajit S. Gill,
President and Chief Executive Officer
3.
